Export Import Guru

Exim SEO is an initiative by Barai Overseas to help its Client to get International reach in Export Business

Categories

OTC vs Rx Pharma Export: The Biggest Strategy Mistake Indian Startups Make

The Biggest Marketing Mistake Pharma Startups Make: OTC vs Prescription-Driven Export Strategy

Are you planning to start a pharmaceutical export business from India with a limited budget?

You may have already selected a product, found an Indian manufacturer, collected quotations and prepared a professional product catalogue.

But one important question remains.

How will your product actually reach its customers?

Many startup merchant exporters spend months learning about pharmaceutical products, technical specifications, manufacturing licences and export documentation.

However, they spend very little time understanding how pharmaceutical products are sold in international markets.

This can become one of their biggest strategic mistakes.

Product knowledge is important, but product knowledge alone does not create sales.

A pharmaceutical business also needs a suitable distribution channel, a marketing strategy, buyer relationships and a clear understanding of the people who influence purchasing decisions.

Two important approaches discussed in pharmaceutical marketing are the OTC-driven model and the prescription-driven model.

Both can create opportunities.

Both require investment.

Both involve competition.

However, their business economics, marketing requirements and customer acquisition methods can be very different.

For Indian startup merchant exporters, understanding these differences before investing money can help prevent costly mistakes.

Let us understand these two models, their advantages, their limitations and how a small entrepreneur can select a practical strategy for entering pharmaceutical markets.

Why Product Knowledge Alone Is Not Enough

Imagine that you want to export a pharmaceutical product from India.

You identify a qualified manufacturer who offers an attractive quotation.

The manufacturer provides a product catalogue, technical specifications and the available quality documents.

You calculate the export price and discover that the product appears competitive.

Naturally, you become excited.

You start contacting international buyers.

But the buyers ask questions that you were not expecting.

Who will market this product locally?

Is there existing demand for the brand?

Does the product require a prescription?

Which pharmacies or distributors will stock it?

Who will convince customers or healthcare professionals to consider it?

What is your marketing budget?

How will the importer recover the cost of launching a new brand?

These questions reveal an important reality.

A product may be technically excellent but commercially unsuccessful if the distribution and marketing strategy is unsuitable.

Therefore, before selecting a pharmaceutical product for export, entrepreneurs should study not only what the product does but also how it will be purchased.

One of the first decisions is understanding the difference between over-the-counter and prescription medicines.

What Is the OTC-Driven Marketing Approach?

OTC stands for Over the Counter.

OTC medicines are products that can legally be supplied without a prescription under the rules of the relevant market.

For example, some medicines used for minor pain, allergies or common cold symptoms may be available without a prescription, depending on their formulation, strength and country.

In an OTC-driven business model, consumer awareness can play an important role in creating product demand.

A company may promote an eligible medicine through permitted advertising, educational content, digital channels and pharmacy-related marketing activities.

Customers may then visit a pharmacy and ask for the product.

However, the exact advertising rules depend on the country.

Not every OTC medicine can be promoted using every advertising method.

For example, Germany distinguishes between prescription medicines, non-prescription pharmacy-only medicines and certain products permitted for sale outside pharmacies.

Therefore, the term OTC should not automatically be interpreted as a product that can be sold anywhere.

How Does an OTC Business Model Work?

Consider a hypothetical Indian company launching a permitted non-prescription healthcare product in an overseas market.

The company selects a product and develops its brand identity.

Next, it appoints an appropriate importer or local distributor.

The distributor arranges supply through legally permitted retail channels.

The company then attempts to increase customer awareness using compliant advertising and educational communication.

Consumers who become interested may ask for the product at pharmacies or other authorized outlets.

In this model, consumer awareness can influence purchasing behaviour.

The company may need to invest in several areas, such as brand development, marketing materials, digital visibility, distribution, pharmacy availability and customer support.

The challenge is that customers often already know established brands.

A new company must give them a genuine reason to consider an unfamiliar product.

Why OTC Marketing Can Be Expensive for Startups

Many entrepreneurs believe that OTC products are easier to sell because the customer does not need a doctor's prescription.

This can be true in some circumstances.

However, easier access does not necessarily mean lower marketing costs.

Imagine that a startup introduces a new OTC brand into a market where several established competitors are already available.

The existing brands may have strong customer recognition, extensive distribution and substantial promotional budgets.

They may already occupy preferred positions in the market.

The startup must therefore solve two problems.

First, it must persuade the customer that its product is worth considering.

Second, the product must be available when the customer wants to purchase it.

Spending money on advertising without sufficient product availability can produce poor results.

Likewise, placing products in retail outlets without generating suitable demand may lead to slow sales and unsold inventory.

Large competitors may have the resources to sustain marketing campaigns for longer periods.

A small startup may not have that financial flexibility.

This is why an OTC launch should be supported by a realistic customer acquisition strategy.

A low manufacturing cost alone is not enough.

The Hidden Cost of Acquiring Customers

Suppose a startup spends money promoting an OTC product.

The entrepreneur sees increasing website traffic and social media engagement.

However, only a small number of people actually purchase the product.

The marketing campaign may appear successful because many people viewed the advertisements.

But financially, it may be unsuccessful.

The important question is how much the company spends to acquire a paying customer.

This is often called Customer Acquisition Cost, or CAC.

A simple approach is to divide the relevant customer acquisition expenses by the number of new customers acquired during the same period.

For example, suppose a company spends ?30,000 on a permitted marketing campaign and acquires 300 new paying customers.

The average acquisition cost would be ?100 per customer.

This is only an illustrative calculation.

It does not represent the actual advertising cost of pharmaceutical products in any particular country.

The company must then determine whether the profit earned from those customers is sufficient to justify the expense.

For a merchant exporter, the more important commercial question may be slightly different.

Can the overseas importer generate enough demand to justify purchasing and maintaining inventory?

This is why understanding the importer's marketing capability is essential before accepting a large order.

What Is the Prescription-Driven or Rx Marketing Model?

Rx is commonly used to refer to prescription medicines.

In a prescription-driven model, a patient requires an appropriate prescription from a qualified healthcare professional before obtaining the medicine.

The healthcare professional selects the treatment according to the patient's medical condition and the applicable clinical guidance.

The patient then obtains the prescribed medicine through an authorized pharmacy or other permitted channel.

For pharmaceutical suppliers, this creates a market where clinical evidence, prescribing requirements, professional information and supply arrangements are important.

However, an exporter cannot simply decide to turn an OTC medicine into a prescription medicine as a marketing technique.

A product's legal classification is determined by the applicable regulatory system.

Likewise, a prescription medicine cannot be marketed directly to consumers simply because the business prefers an OTC-style approach.

A pharmaceutical marketing strategy must always fit the product's legally authorized status.

How Prescription-Driven Pharmaceutical Sales Work

Consider a hypothetical company supplying a registered prescription medicine through an authorized distributor.

The product has the relevant regulatory approval.

The manufacturer provides the required technical and quality documentation.

The local distributor manages authorized commercial supply.

Appropriately trained professionals may communicate scientifically accurate product information to healthcare professionals where local law permits.

Doctors make independent treatment decisions according to patient needs and medical evidence.

Patients obtain the prescribed medicine through authorized dispensing channels.

This model differs from consumer-led OTC marketing.

The company does not normally need to make the general public recognize the brand through mass advertising.

However, the company may face different expenses.

These can include scientific documentation, medical information activities, regulatory work, authorized distribution, professional engagement and ongoing compliance.

Therefore, prescription-driven marketing is not free or automatically inexpensive.

It simply uses a different route to market.

Why the Video Recommends Prescription-Driven Marketing for Small Startups

The central argument of the video is that a small pharmaceutical startup should not automatically choose an OTC-driven strategy simply because OTC products are easier for consumers to purchase.

The video highlights the difficulty of competing against established consumer brands with large advertising budgets.

It suggests that healthcare-professional-led markets may provide opportunities to develop more focused, long-term relationships.

There is an important business lesson in this argument.

A small company often cannot compete effectively by attempting to reach an entire population.

It may be better positioned to serve a specific customer group with clearly defined needs.

For example, a startup may find it more manageable to understand the requirements of selected authorized distributors than to launch a large national consumer advertising campaign.

However, this does not mean that prescription-driven selling is always the better choice.

The correct strategy depends on the product, market, regulatory pathway, competition, financial resources and distribution system.

A startup should select the approach that fits its actual capabilities.

Why Doctor Relationships Can Matter in Pharmaceutical Markets

Doctors and other qualified healthcare professionals play an important role in the use of prescription medicines.

They evaluate patients, diagnose conditions and prescribe suitable treatments.

Their decisions are influenced by clinical evidence, professional guidance, product availability and the individual patient's medical needs.

Therefore, companies supplying prescription medicines must understand the information healthcare professionals require.

For example, important questions may include:

What is the medicine's approved indication?

What evidence supports its efficacy?

What are the relevant safety considerations?

How does it compare with suitable alternatives?

What are the approved dosage and administration requirements?

Are there important contraindications or interactions?

Is the product consistently available?

These are legitimate scientific and practical questions.

A pharmaceutical company that can provide accurate information may be better equipped to support the local market.

However, professional engagement must not involve improper financial inducements or attempts to influence prescribing against the patient's interests.

Clinical independence is essential.

An Indian merchant exporter should work through appropriately authorized local partners and follow the destination country's promotional rules.

Why Prescription-Driven Selling Does Not Guarantee Long-Term Sales

Some entrepreneurs assume that if a doctor begins prescribing a particular medicine, the business will continue receiving orders indefinitely.

This is not necessarily true.

Several factors can influence long-term pharmaceutical sales.

A doctor's prescribing practices may change because of new clinical evidence or treatment guidelines.

New medicines may enter the market.

Generic competition may increase.

Government reimbursement rules may change.

A pharmacy may dispense a permitted equivalent product instead of the brand originally prescribed.

A manufacturer may face supply problems.

The importer may lose a distribution contract.

Therefore, a prescription-driven business can still experience competition and market changes.

The stronger long-term strategy is to develop a compliant, dependable supply system supported by appropriate product evidence and commercial relationships.

The Mistake of Assuming Doctors Control All Pharmacies

The video discusses pharmacies located near hospitals or connected with healthcare facilities.

Such relationships may influence local purchasing patterns in some markets.

However, it would be inaccurate to assume that most pharmacies worldwide are owned or controlled by doctors.

Pharmacy ownership and dispensing rules vary considerably between countries.

For example, Germany has a regulated pharmacy system in which pharmacists play an independent professional role.

Doctors do not automatically control the medicine brands dispensed by pharmacies.

In addition, German health-insurance arrangements can influence which generic medicines are supplied.

This demonstrates why exporters must study the actual structure of the destination market rather than apply the same sales assumptions everywhere.

Germany provides an interesting example.

Understanding Germany's Pharmaceutical Market

Germany is an important European pharmaceutical market with established medical services, pharmacies, manufacturers, distributors and health-insurance arrangements.

For Indian pharmaceutical exporters, Germany may be worth investigating because of its developed healthcare infrastructure and demand for regulated medicines.

However, it is not automatically an easy market for new exporters.

Germany operates within the European Union's pharmaceutical regulatory system.

This means products generally require appropriate marketing authorization before being placed on the market.

Manufacturing, importing, packaging, distribution and advertising are also subject to strict requirements.

For startups, the opportunity is to identify suitable German or European business partners and understand how the regulated supply chain works.

The opportunity should not be confused with permission to sell an Indian medicine directly to German pharmacies.

Why Germany Is Not Simply a Doctor-Driven Market

Germany provides an important example of why a startup must study the complete pharmaceutical purchasing process.

A doctor may prescribe a medicine, but the exact product dispensed may also be influenced by pharmacy substitution requirements and statutory health-insurance contracts.

Germany uses a system commonly referred to as the Aut-idem rule.

Under applicable conditions, a pharmacist may supply an equivalent medicine containing the same active ingredient instead of the originally named product.

Health insurers may also have rebate agreements with particular manufacturers.

These agreements can influence which generic product a pharmacy dispenses.

Therefore, a new Indian generic medicine cannot depend only on persuading doctors to prescribe its brand.

Its commercial success may also depend on pricing, reimbursement, insurer arrangements, pharmacy availability and distribution.

For a startup merchant exporter, this can be more important than spending money on brand promotion.

A company must understand who actually decides what is purchased and supplied.

Germany and the Difference Between OTC and Prescription Marketing

Germany has specific rules concerning the promotion of medicines.

Its Heilmittelwerbegesetz, commonly called the HWG, regulates healthcare advertising.

Under Section 10, advertising of prescription medicines is restricted to specified professional audiences.

General public advertising of prescription medicines is not permitted.

Non-prescription medicines may have different advertising possibilities, but those activities remain regulated.

Therefore, an Indian exporter cannot use the same digital marketing campaign for both OTC and prescription products.

The local regulatory status and permitted promotional audience must be confirmed first.

This also means that an exporter cannot assume that a doctor-focused approach is automatically easier or cheaper.

Professional pharmaceutical communication requires appropriate expertise, documentation and legal compliance.

How Indian Pharmaceutical Products Can Enter Germany

For conventional medicines, the European Union provides several marketing authorization pathways.

These include the national procedure, decentralized procedure, mutual recognition procedure and centralized procedure.

The correct route depends on the product and the countries where the company intends to market it.

The European Medicines Agency is involved in the centralized pathway, while national authorities manage the applicable national and coordinated procedures.

In Germany, the Federal Institute for Drugs and Medical Devices, known as BfArM, is an important competent authority for relevant medicinal products.

Some products fall under other responsible authorities, depending on their category.

For a startup merchant exporter, understanding the regulatory pathway is essential.

A manufacturer holding an Indian drug manufacturing licence cannot automatically begin selling that medicine in Germany.

The company must work through an appropriate authorized supply arrangement.

What Is EU GMP and Why Does It Matter?

GMP stands for Good Manufacturing Practice.

GMP requirements help ensure that pharmaceutical products are consistently manufactured and controlled according to appropriate quality standards.

European pharmaceutical manufacturing and import activities are subject to applicable EU GMP requirements.

For an Indian manufacturer supplying finished medicines to Germany, this may require demonstrating compliance with relevant European requirements.

The European importer must also hold the appropriate authorization for its activities.

Finished medicines imported from outside the EU/EEA generally require the applicable import controls and Qualified Person certification before release to the European market.

A Qualified Person, often called a QP, has specific legal responsibilities for verifying that a pharmaceutical batch meets the applicable requirements.

This is an important difference between ordinary merchandise and regulated medicines.

For a startup merchant exporter, partnering with the right manufacturer and authorized European importer is essential.

A competitive quotation cannot replace these requirements.

German Language Packaging and Medicine Traceability

Another important consideration is packaging and labelling.

Medicines supplied in Germany generally require the applicable German-language product information.

This may include appropriate labels and patient information leaflets.

Many prescription medicines also require anti-falsification safety features under the European regulatory framework.

Depending on the product, these can include a unique identifier and an anti-tampering device.

These features help support medicine authentication and supply-chain safety.

Therefore, an Indian manufacturer may need to prepare Germany-specific packaging that meets the approved product requirements.

A startup should confirm these details before calculating the commercial cost of exporting.

An ordinary Indian domestic-market pack should not be assumed suitable for German commercial distribution.

Can the India–EU Free Trade Agreement Help Pharmaceutical Exporters?

The video discusses the potential benefit of a trade agreement between India and Europe.

This is relevant because trade agreements can influence tariffs, customs procedures and market-access conditions.

India and the European Union concluded negotiations for their Free Trade Agreement on 27 January 2026.

The European Commission subsequently advanced the agreement toward the formal approval process.

However, as of 3 November 2026, the agreement had not yet entered into force.

Therefore, exporters should not calculate current shipments using future preferential terms that are not yet legally applicable.

There is another important distinction.

Even when a trade agreement reduces duties or improves trade procedures, it does not automatically remove pharmaceutical registration requirements.

For example, a medicine may benefit from a future tariff concession but still require appropriate European marketing authorization, manufacturing compliance and import arrangements.

The practical lesson is to study trade agreements carefully while keeping customs benefits separate from product regulatory approval.

Why Innovation Alone Does Not Make Germany Easy to Enter

The video suggests that Germany may be receptive to new healthcare products and innovation.

Innovation can be commercially important, but market acceptance cannot be assumed.

Germany is also a highly regulated and competitive pharmaceutical market.

A new product may require significant scientific and regulatory evaluation.

Even after authorization, it may face established competitors, reimbursement considerations and complex distribution arrangements.

Therefore, an Indian startup should not choose Germany merely because its product has a new ingredient, packaging design or marketing claim.

A genuinely differentiated product needs suitable evidence and legal authorization.

A startup may find an opportunity through an established German importer seeking a reliable alternative manufacturer.

That can be a more practical starting point than attempting to launch an entirely new consumer or prescription brand independently.

The Third Strategy Startups Often Overlook: B2B Distributor-Driven Selling

The video focuses on two marketing approaches.

However, for Indian merchant exporters, a third commercial approach deserves serious attention.

This is B2B distributor-driven selling.

B2B means Business to Business.

In this model, the Indian merchant exporter does not attempt to advertise directly to every patient or independently influence doctors.

Instead, the exporter works with qualified international importers, marketing authorization holders, distributors or other appropriate partners.

The overseas partner understands the local market and is responsible for the activities assigned to it under the applicable legal and commercial arrangement.

For example, an Indian merchant exporter may identify a manufacturer capable of supplying an approved generic formulation.

The exporter then approaches a suitable European pharmaceutical company to investigate whether additional sourcing is required.

The local partner evaluates the product, manufacturer, regulatory documentation and commercial terms.

If the arrangement is suitable, the parties may develop a supply agreement.

This approach can allow a startup to concentrate on sourcing, documentation, pricing and supply coordination rather than building a large overseas marketing operation.

However, it does not eliminate regulatory requirements.

A local partner can provide necessary capabilities, but the product and transaction must still comply with the law.

How to Choose Between OTC, Rx and B2B Distribution

Before selecting a sales strategy, ask several practical questions.

Is the product legally classified as prescription-only or non-prescription in the target country?

Does it already have the necessary market authorization?

Who is the actual buyer?

Does the importer already have distribution capabilities?

Will the exporter be responsible for consumer promotion?

Is professional scientific communication required?

How much marketing investment is necessary?

Will the manufacturer provide technical and regulatory support?

Can the importer provide realistic order forecasts?

Who bears the cost of product registration and market development?

The answers will help determine which business model is commercially realistic.

For example, a startup with limited marketing capital but strong manufacturing relationships may prefer a B2B sourcing role.

Another company with an established local consumer distribution network may investigate suitable OTC opportunities.

A business experienced in regulated prescription medicines may work through authorized Rx distribution channels.

There is no universal best model.

The correct decision depends on the actual product and market.

A Simple Comparison of OTC and Prescription-Driven Business

OTC-Driven Model

The customer can legally purchase the eligible medicine without a prescription.

Consumer awareness and pharmacy availability may be important.

Companies may use permitted public advertising and other lawful communication channels.

A new brand may require significant promotional investment.

However, some OTC products can also be sold successfully through focused distribution, pharmacy recommendation, existing retail relationships and other commercially suitable channels.

Prescription-Driven Model

The medicine requires an appropriate prescription.

Clinical evidence, approved product information and healthcare-professional communication are relevant.

Public promotion of prescription medicines is prohibited or restricted in many regulated markets.

Market access can depend on professional guidance, pharmacy dispensing, reimbursement systems and distribution agreements.

Regulatory and scientific communication costs may be substantial.

B2B Distributor-Driven Model

The Indian exporter supplies through a suitable international business partner.

The exporter may concentrate on sourcing, manufacturer selection, quality documentation and shipment coordination.

The local partner manages its agreed regulatory, import, distribution and marketing responsibilities.

This model can be relevant to both OTC and prescription products.

Therefore, B2B distribution should not be understood as a separate legal classification of medicine.

It is a commercial route to market.

The Most Important Question for Merchant Exporters

Many startup entrepreneurs ask:

"Should I export OTC medicines or prescription medicines?"

A more useful question is:

"Which product and distribution arrangement can I manage responsibly with my available budget, manufacturer relationships and market knowledge?"

For example, if your target market requires expensive product registration, the cost may be more important than whether the product is OTC or Rx.

If your buyer already has a suitable authorized product and needs an additional manufacturing source, the opportunity may be more manageable.

If you are trying to establish a new consumer brand, advertising and retail distribution costs may become major considerations.

If you are supplying a prescription medicine, regulatory and scientific requirements may dominate the business plan.

Therefore, choose the complete business model, not simply the medicine category.

How Startup Merchant Exporters Can Find Their First International Buyers

A small company should avoid approaching international buyers without understanding their business.

Begin by selecting one product category.

Then identify relevant importers, distributors and pharmaceutical companies.

Study their existing product portfolios.

Find out whether they operate in the OTC, prescription or mixed pharmaceutical market.

Next, examine whether your proposed manufacturer or product is likely to match their requirements.

For example, a company already distributing generic prescription medicines may be interested in reviewing an additional qualified Indian manufacturing source.

A pharmacy-focused OTC distributor may have different requirements.

A hospital procurement organization may prioritize another set of specifications.

The more closely your product matches the buyer's existing business, the more meaningful your introduction can become.

However, do not assume that every distributor is looking for new products.

Your first objective should be to understand the buyer's needs.

How to Convince a Buyer Without a Large Marketing Budget

Imagine that a German pharmaceutical distributor already purchases generic medicines from established manufacturers.

You contact the company as a new Indian merchant exporter.

If you simply say that your products are cheaper, the buyer may not be interested.

Instead, discuss specific supply requirements.

For example, ask whether the company is evaluating additional manufacturing sources or needs particular product specifications.

If your manufacturer has suitable technical documentation and relevant regulatory experience, explain what information can be made available for evaluation.

You may be able to coordinate manufacturer details, product dossiers, qualified supply arrangements and commercial quotations.

However, the exporter should offer only services it can genuinely provide.

The objective is not to convince buyers through exaggerated promises.

It is to reduce uncertainty and show practical value.

A Practical Introductory Email for European Pharma Buyers

Subject: India–Europe Pharmaceutical Sourcing – Product and Supply Discussion

Dear Procurement Team,

Greetings from Barai Overseas, India.

We work in international business development and sourcing coordination for selected pharmaceutical and healthcare products.

We are exploring opportunities to support European pharmaceutical companies seeking suitable Indian manufacturing partners and reliable supply arrangements.

We understand that product quality, regulatory documentation, manufacturing compliance and supply continuity are important considerations in the European market.

We would be interested in learning whether your organization is evaluating additional sourcing options for any existing or planned product categories.

Based on the specific requirement and manufacturer capability, we can coordinate available product specifications, manufacturing information, technical documentation and commercial quotations for your review.

We would welcome the opportunity to understand your current procurement priorities and determine whether a suitable supply arrangement could be developed.

Best regards,

Barai Overseas

https://www.exportimport.guru/

This introductory communication focuses on business sourcing rather than unapproved medicinal product promotion.

Any product-specific marketing claims must be appropriate for the intended recipient and comply with the relevant local requirements.

What Should a Startup's Marketing Budget Cover?

Before deciding on OTC or Rx, prepare a proper marketing and market-entry budget.

The budget should distinguish between several different activities.

The first is product and market research.

This includes understanding the target country, competing products, regulatory pathway and relevant customer groups.

The second is manufacturer evaluation.

This may involve obtaining documents, arranging samples and reviewing technical capabilities.

The third is regulatory preparation.

Depending on the product, this may involve registration-related documentation and other market-access expenses.

The fourth is buyer development.

This may include suitable trade events, professional communication, sales materials and authorized local business partners.

The fifth is logistics and commercial execution.

The exporter must calculate transport, documentation, packaging, payment and other relevant costs.

Finally, some money should be reserved for unexpected expenses.

The objective is not to spend the entire budget on promotion before establishing that the product can legally and commercially enter the market.

Why Consumer Advertising May Not Be the Right First Expense

Suppose a startup has a limited investment budget.

It spends most of its money on advertisements for a product intended for an overseas market.

Customers begin enquiring about the product.

However, the importer has not yet established the necessary distribution arrangements or regulatory requirements.

The company may be unable to fulfil those enquiries.

This creates wasted expenditure and possible legal risk.

A better approach is to establish market readiness first.

Confirm product classification.

Verify market authorization.

Identify a suitable importer.

Understand distribution requirements.

Calculate the complete supply cost.

Then decide whether any promotional investment is commercially justified and legally permitted.

This is especially important for healthcare products.

Marketing should support a lawful and reliable supply system rather than attempt to create demand before the product is ready.

How to Evaluate Marketing Return on Investment

Startup exporters should not judge a marketing strategy only by the number of enquiries it produces.

The quality of the enquiries matters.

For example, a company may receive 500 enquiries from general consumers but have no authorized local retail channel.

Another company may receive five enquiries from qualified pharmaceutical distributors.

Those five enquiries may be more commercially relevant.

However, neither number guarantees sales.

A practical evaluation should consider the quality of buyers, conversion into technical discussions, documentation readiness, registration feasibility, expected order value and projected margin.

The exporter should also consider the time needed to convert an enquiry into a commercial order.

For regulated pharmaceutical markets, the sales process may involve substantial technical and regulatory review.

Therefore, the cheapest marketing channel is not necessarily the most effective.

The goal should be to achieve commercially meaningful opportunities at a manageable cost.

Why a Small Geographic Market Can Be a Sensible Starting Point

The video highlights that a focused prescription-led business may establish consistent sales even when the brand has limited geographic coverage.

This contains an important business principle.

A startup does not need to enter an entire country immediately.

It may be more practical to work with a qualified distributor serving a defined region or customer group.

For example, a suitable local partner may already supply selected pharmacies, hospitals or healthcare institutions.

The exporter can investigate whether its products fit the partner's current requirements.

This can reduce the need to build an extensive distribution system from the beginning.

However, the agreement must account for applicable competition, distribution and pharmaceutical regulations.

A small territory does not automatically guarantee consistent orders.

The opportunity depends on genuine demand and reliable commercial arrangements.

The Importance of Repeated Orders

For many merchant exporters, the goal is not simply to complete one shipment.

The objective is to develop recurring business.

A repeat order generally indicates that the buyer continues to find commercial value in the supply arrangement.

However, repeat orders are influenced by several factors.

These include product quality, pricing, lead times, inventory requirements, customer demand, competition and regulatory compliance.

A merchant exporter should maintain regular communication with the buyer and manufacturer.

For example, the exporter can coordinate realistic production forecasts and identify upcoming documentation or packaging requirements.

This helps reduce avoidable supply interruptions.

The most valuable business relationship is not always the one with the highest first order.

It may be the relationship that produces dependable, profitable business over time.

What Indian Startups Should Check Before Selecting Germany

Germany is worth researching, but it requires careful preparation.

A startup should begin with one clearly defined pharmaceutical product.

Then examine its legal classification and market authorization status.

Next, research the relevant European regulatory pathway.

Identify whether the Indian manufacturer has appropriate GMP documentation and experience with European requirements.

Understand the role of the European importer, marketing authorization holder and Qualified Person.

Study the local distribution system, including pharmacies, wholesalers and health-insurance arrangements where relevant.

Check German-language labelling and applicable medicine traceability requirements.

Finally, identify suitable local companies that may have a real interest in additional sourcing.

This approach is more reliable than assuming that Germany offers easy entry because of demand for innovation.

A startup should only proceed when product-level feasibility can be demonstrated.

A 60-Day Preparation Plan for Startup Merchant Exporters

Days 1–10: Understand the Product

Select one medicine or healthcare product category.

Study its intended use, manufacturing requirements and regulatory classification.

Identify whether it is prescription-only or non-prescription in the target country.

Days 11–20: Research the Market

Study the existing brands, competing manufacturers, distributor networks and relevant market-access requirements.

If Germany is the target, examine the applicable European regulatory pathway and local distribution system.

Days 21–30: Evaluate Manufacturers

Request manufacturer profiles, product specifications, relevant licences and available technical documentation.

Determine whether the manufacturer has experience supplying regulated international markets.

Days 31–40: Identify the Commercial Strategy

Decide whether the opportunity involves an existing authorized product, additional sourcing for an established distributor or a new market-entry project.

Prepare a realistic cost and responsibility assessment.

Days 41–50: Prepare Buyer Communication

Develop a focused company presentation and suitable introductory emails.

Identify relevant importers, distributors and marketing authorization holders.

Avoid unsupported clinical claims or premature product promotion.

Days 51–60: Begin Market Validation

Contact suitable business partners.

Understand their requirements, available opportunities and commercial expectations.

Review buyer feedback and decide whether the proposed product warrants further investment.

This is a preparation roadmap rather than a guarantee that pharmaceutical exports can begin within 60 days.

Actual commercial timelines depend on regulatory approvals, manufacturer readiness and buyer requirements.

Common Strategic Mistakes Pharma Startups Should Avoid

One common mistake is selecting an OTC product simply because customers can buy it without a prescription.

Another is assuming that prescription-driven products require little marketing expenditure.

Some entrepreneurs believe that doctors control every pharmaceutical purchasing decision.

Others underestimate the influence of pharmacies, distributors, insurers and reimbursement systems.

Another mistake is selecting Germany or another regulated market based only on its size or reputation.

Some startups also assume that a new trade agreement immediately removes pharmaceutical regulatory requirements.

Others spend money on advertising before confirming registration, product availability or distribution.

Another common problem is trying to compete directly with large brands without identifying a genuine customer need.

Finally, some exporters confuse a manufacturer's product quality with their own ability to create international sales.

All these mistakes can be reduced through careful market research and business planning.

The Better Strategy: Understand the Buyer Before Choosing the Marketing Channel

The most important lesson from this discussion is that pharmaceutical marketing should begin with understanding the buyer.

Different products have different customers and different decision-making processes.

For an OTC medicine, consumer awareness and pharmacy availability may be important.

For a prescription medicine, healthcare professionals, clinical evidence and regulated distribution play important roles.

For generic medicines in Germany, health insurers, pharmacy substitution rules, regulatory approvals and commercial supply arrangements can be highly influential.

For an Indian merchant exporter, the direct buyer may actually be an authorized pharmaceutical importer or distributor rather than the final patient.

Therefore, the exporter should understand the complete purchasing chain.

Who approves the product?

Who imports it?

Who distributes it?

Who decides whether to stock it?

Who prescribes or recommends it, where applicable?

Who ultimately pays for it?

And who has the authority to make the commercial purchase?

Once these questions are answered, selecting a marketing strategy becomes much easier.

Final Thoughts: The Biggest Strategic Mistake Is Choosing Marketing Before Understanding the Market

The biggest strategic mistake pharmaceutical startups make is not necessarily choosing OTC instead of prescription medicines.

The deeper mistake is selecting a sales approach without first understanding the product, market, customer and regulatory requirements.

Many entrepreneurs believe that success depends only on product quality and attractive pricing.

However, even a good product may fail commercially if the exporter does not understand how it reaches customers.

OTC products can require substantial consumer marketing investment.

Prescription medicines can require professional scientific communication and complex regulatory arrangements.

Established generic markets may also be influenced by pharmacies, insurers, distributors and reimbursement rules.

For Indian startup merchant exporters, a focused B2B sourcing strategy may sometimes be more manageable than trying to build an overseas pharmaceutical brand independently.

But this decision must be based on actual commercial feasibility.

Start with one product.

Understand its legal classification.

Study the destination market.

Identify the actual purchasing decision-makers.

Evaluate qualified manufacturers.

Confirm the regulatory pathway.

Select a suitable commercial partner.

Calculate realistic costs.

Then choose the marketing strategy that fits your resources.

Remember one important business principle:

A pharmaceutical product does not become successful merely because it is good. It becomes commercially viable when the right product reaches the right customer through a lawful, reliable and economically sustainable supply system.

At Barai Overseas, we focus on helping Indian entrepreneurs understand pharmaceutical product selection, international market research, manufacturer sourcing, regulatory challenges and practical merchant-export strategies.

Our objective is to help startups make informed business decisions before committing their limited capital.

Watch Our Original Video

The Big Strategic Mistake Pharma Startups Make

https://www.youtube.com/watch?v=0OPjI4eRj9g

For more practical pharmaceutical export-import learning resources, visit:

https://www.exportimport.guru/

Useful Official References